Another step towards a future commercialization, important, but hardly any motivation to buy for new investors.
Anyway, NK is used to treat some type of blood cancers where CD19 CAR-Ts won't work. Filling that gap is worth a lot and definitely more than what CHM is currently valued at. The AML trials could be the jump board although the tech has already proven to produce remarkable results. MD Anderson has a very high reputation, choosing CHM's 0201 isn't a result of a "Texas Saloon" lunch, it has been chosen for a reason.
GLTA
- Forums
- ASX - By Stock
- CHM
- Ann: US patent allowed for CHM 0201 (CORE-NK) technology
Ann: US patent allowed for CHM 0201 (CORE-NK) technology, page-8
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online